주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
국내의약뉴스
성상변경내역
약제급여기준 개정내역
제약업계 소식
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
뇌심혈관계
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
미용
기타
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
62nd European Renal Association Congress (ERA 2025)
04 June - 07 June, 2025, Austria
Analogue bests human insulin in T2D patients with kidney failure on peritoneal dialysis
2025-09-17
Analogue insulin demonstrates superiority over human insulin in terms of survival among patients with kidney failure and type 2 diabetes (T2D) who are receiving peritoneal dialysis, according to a study presented at ERA 2025.
CONFIDENCE supports simultaneous MR, SGLT2 inhibition in CKD and T2D
2025-09-17
The phase II CONFIDENCE* trial shows the benefit of dual therapy with the selective ns-MRA** finerenone and the SGLT2i** empagliflozin vs either agent alone in individuals with chronic kidney disease (CKD) and type 2 diabetes (T2D).
Glucose-lowering med shows promise for treating kidney stones in nondiabetics
2025-09-17
Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin helps improve the urinary lithogenic risk profile of nondiabetic patients with calcium and uric acid stones, as shown in the results of the randomized crossover SWEETSTONE trial.
How does finerenone fare among DKD patients in real life?
2025-09-17
In patients with chronic kidney disease and type 2 diabetes who have not been previously treated with any mineralocorticoid receptor antagonist (MRA), the use of finerenone results in marked reductions in albuminuria, reports a study presented at ERA 2025.
IgAN drug hits target in phase III study
2025-09-17
The selective immunoglobulin (Ig)G2 antibody sibeprenlimab reduces proteinuria in individuals with IgA nephropathy (IgAN) in an interim analysis of the phase III VISIONARY study.
Pegcetacoplan delivers in rare CMKDs causing nephrotic-range proteinuria
2025-09-17
In patients with either C3G or primary IC-MPGN presenting with nephrotic-range proteinuria, treatment with pegcetacoplan reduces proteinuria and C3c renal biopsy staining and stabilizes kidney function, according to results from a post hoc analysis of VALIANT presented at ERA 2025
Targeted-release budesonide formulation makes good in IgAN regardless of baseline eGFR
2025-09-17
Treatment with targeted-release budesonide formulation preserves kidney function and reduces proteinuria in patients with IgA nephropathy (IgAN) independent of baseline eGFR, and this benefit is seen both after 9 months of treatment and throughout the remaining 15-month off-treatment period, according to a subanalysis of the phase III NeflgArd study presented at the ERA annual meeting.
Which kidney failure patients would benefit most from HDF instead of HD?
2025-09-17
Younger patients and those with fewer comorbidities benefit most from haemodiafiltration (HDF) instead of conventional haemodialysis (HD), according to a multitrial model presented at ERA 2025.
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
